Ask about this productRelated genes to: GRIA1 antibody
- Gene:
- GRIA1 NIH gene
- Name:
- glutamate ionotropic receptor AMPA type subunit 1
- Previous symbol:
- GLUR1
- Synonyms:
- GluA1, GLURA
- Chromosome:
- 5q33.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-02-13
- Date modifiied:
- 2016-10-06
Related products to: GRIA1 antibody
Related articles to: GRIA1 antibody
- Tic disorder (TD) is a neurodevelopmental condition for which pharmacological treatments are limited and are frequently associated with side effects. Jingxin Zhidong formula (JXZDF) offers a potential alternative therapy; however, its mechanism of action has not been fully elucidated. This study investigated the therapeutic effects of JXZDF on TD and explored underlying mechanisms involving neurotransmitter regulation and microglial IκB kinase/nuclear factor-κB (IKK/NF-κB) signaling, a pathway implicated in both inflammatory activation and metabolic reprogramming. - Source: PubMed
Fan FeiYang JingNiu ZenghuiXiu ChengkuiHan Fei - Pediatric gliomas, comprising both low-grade (LGGs) and high-grade gliomas (HGGs), exhibit significant molecular and clinical heterogeneity. While LGGs generally have a favorable prognosis, HGGs are associated with poor long-term survival despite aggressive treatment. Advances in molecular profiling have enabled targeted therapies, but treatment resistance and tumor heterogeneity remain major challenges. The integration of artificial intelligence (AI) and transcriptomic data holds promise for refining prognostic models and guiding personalized treatment strategies, yet its application in pediatric gliomas remains underexplored. - Source: PubMed
Publication date: 2026/03/09
Li GanglongPei FuyuWang Weizhen - The link between impaired gamma oscillations and Alzheimer's disease (AD) has inspired therapies using rhythmic physical stimuli. However, given that cognition requires cross-frequency interactions like theta-gamma coupling, single-frequency stimulation may yield limited benefits. This study therefore applied a compound pulsed magnetic field (cPMF) with theta rhythm-modulated gamma frequency to evaluate its efficacy and mechanisms against AD pathology compared with single gamma-frequency pulsed magnetic field (sPMF). Local field potential results showed that cPMF outperformed sPMF by significantly enhancing hippocampal oscillations and particularly rescuing the impaired theta-gamma phase-amplitude coupling in AD mice, which was positively correlated with improved cognitive performance in behavioral tests. Correspondingly, cPMF treatment enhanced blood flow perfusion in the prefrontal and cerebral cortices of AD mice, which may contribute to amyloid-β clearance and neuroinflammation attenuation. At the molecular level, cPMF rescued AD-related transcriptional alterations by upregulating key genes involved in cholinergic signaling (Chat, Chrm1), glymphatic function (Aqp4), and synaptic plasticity (Gria1, an AMPA receptor subunit). These findings indicated that cPMF stimulation achieved multi-level restorative effects by enhancing neuronal activity, promoting cerebral perfusion, facilitating amyloid-β clearance, and rectifying aberrant gene expression, ultimately leading to cognitive improvement in AD mice. This cPMF stimulation paradigm highlights the therapeutic potential of targeting endogenous oscillatory interactions for treating neurological disorders. - Source: PubMed
Publication date: 2026/03/18
Wang XueWang XutingZhao HaoyuZhao ChunchengWang PingpingSong Tao - L-theanine is a bioactive non-protein amino acid predominantly derived from tea plants (), widely recognized for its potential benefits in mood regulation and psychological health. Despite its promising neuropsychological profile, the specific molecular targets and mechanisms underlying its antidepressant activity remain incompletely understood. In the present study, an integrated network pharmacology strategy, combined with molecular docking and molecular dynamics (MD) simulations, was employed to systematically elucidate the potential antidepressant mechanisms of L-theanine. By intersecting predicted drug targets with depression-related genes, 40 potential targets were identified. Protein-protein interaction (PPI) network analysis subsequently pinpointed five hub targets: PRKACA, GRIA2, GRIN1, GRIA1, and HTR1A. Functional enrichment analyses (KEGG and GO) indicated that these targets are primarily implicated in critical pathological processes of depression, including neurotransmitter regulation, glutamatergic synaptic transmission, stress response signaling, and neurotrophin-related pathways. Molecular docking revealed favorable binding affinities between L-theanine and the key targets. Furthermore, MD simulations and binding free energy calculations corroborated the structural stability and thermodynamic favorability of these protein-ligand complexes. Overall, this study provides hypothesis-generating insights into the antidepressant mechanisms of L-theanine from a multi-target perspective, offering a theoretical foundation to guide future experimental validation in depression research. - Source: PubMed
Publication date: 2026/02/04
Shi YutaoYang YuanCheng XiHuang CanyangHuang YanLu LiWang ShuyanZheng YuchengWang FeiquanZhang BoZheng Shulin - Clinical risk factors for seizure presentation in meningioma patients have been reported, but molecular correlates of seizures in meningioma remain unexplored. - Source: PubMed
Publication date: 2026/02/12
Khan A BasitMcDonald Malcolm FEnglish CollinNouri Shervin HKatlowitz Kalman ALau SeanPatel RajanRojas DiegoHarmanci ArifJalali AliRao GaneshPichumani KumarHarmanci Akdes SKlisch Tiemo JPatel Akash J